Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock

Alkermes plc (NASDAQ:ALKS) EVP Craig Hopkinson sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $29.72, for a total value of $267,480.00. Following the completion of the sale, the executive vice president owned 89,389 shares in the company, valued at $2,656,641.08. The trade was a 9.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alkermes Stock Performance

Alkermes stock opened at $28.35 on Friday. The firm has a market cap of $4.72 billion, a price-to-earnings ratio of 19.83, a PEG ratio of 7.30 and a beta of 0.53. Alkermes plc has a 52-week low of $25.17 and a 52-week high of $36.32. The firm has a 50 day moving average price of $31.59 and a two-hundred day moving average price of $30.23.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.14). The firm had revenue of $384.55 million for the quarter, compared to analyst estimates of $380.44 million. Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The company’s quarterly revenue was down 10.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.05 earnings per share. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. As a group, equities research analysts predict that Alkermes plc will post 1.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Alkermes

Several hedge funds and other institutional investors have recently made changes to their positions in ALKS. Assetmark Inc. lifted its position in Alkermes by 933.8% in the 3rd quarter. Assetmark Inc. now owns 827 shares of the company’s stock valued at $25,000 after acquiring an additional 747 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new stake in shares of Alkermes in the fourth quarter worth approximately $28,000. Johnson Financial Group Inc. bought a new position in shares of Alkermes in the third quarter valued at approximately $31,000. UMB Bank n.a. boosted its position in shares of Alkermes by 57.6% during the fourth quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock valued at $34,000 after buying an additional 446 shares during the last quarter. Finally, Salomon & Ludwin LLC boosted its position in shares of Alkermes by 115.6% during the fourth quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock valued at $35,000 after buying an additional 667 shares during the last quarter. 95.21% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ALKS shares. Wells Fargo & Company raised their target price on Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Royal Bank Of Canada cut their price target on Alkermes from $47.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. Wall Street Zen lowered shares of Alkermes from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Wolfe Research assumed coverage on shares of Alkermes in a research report on Monday, February 23rd. They set an “outperform” rating and a $45.00 target price on the stock. Finally, HC Wainwright restated a “neutral” rating and issued a $43.00 price target on shares of Alkermes in a report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $44.07.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.